- Your selection
- Clear all
- Biotechnology x
- English x
- With Teaching Note x
13 cases found.
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
- By
Reference 6684
Published 15 Nov 2021
Region Europe
Industry Biotechnology
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
- By
Reference 6684
Published 15 Nov 2021
Industry Biotechnology
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
- By
Reference 6684
Published 15 Nov 2021
Region Europe
Industry Biotechnology
Kusha Ahmad is tasked with facilitating headcount reduction following the acquisition of the Societe Francaise de Biotechnologie (SFB) by Big American Pharmaceuticals (BAP), and the subsequent closure of the SFB office in Lyon, France. In accordance with regulations introduced in 2017, staff are entitled to a “rupture conventionnelle collective”.
Praesens Care, a start-up based in Belgium, has developed a mobile laboratory with the aim of safely testing people for a wide range of killer diseases. Its mobile laboratories enable monitoring of infectious diseases and improve diagnostic capabilities in remote areas in Africa.
- By
Reference 6598
Published 23 Mar 2021
Topic Operations
Region Global
Industry Biotechnology
Praesens Care, a start-up based in Belgium, has developed a mobile laboratory with the aim of safely testing people for a wide range of killer diseases. Its mobile laboratories enable monitoring of infectious diseases and improve diagnostic capabilities in remote areas in Africa.
In 2013, Eastern Health Alliance (EHA) launched the Neighbours for Active Living programme to reduce hospital readmissions among seniors in eastern Singapore. At its core, ‘Neighbours’ addressed the health care and social needs of high-risk residents within their homes, while building social support systems around them through community outreach.
- By
Reference 6336
Published 27 Nov 2017
Topic Operations
Region Asia
Industry Biotechnology
In 2013, Eastern Health Alliance (EHA) launched the Neighbours for Active Living programme to reduce hospital readmissions among seniors in eastern Singapore. At its core, ‘Neighbours’ addressed the health care and social needs of high-risk residents within their homes, while building social support systems around them through community outreach.
PatientsLikeMe, an online health community formed to provide value for patients in exchange for sharing their health data, had grown substantially since its founding in 2004. By 2016 it had over 130 employees. However, convincing investors of the viability of the business model proves more challenging.
- By
Reference 6248
Published 30 Jan 2017
Topic Operations
Region North America
Industry Biotechnology
PatientsLikeMe, an online health community formed to provide value for patients in exchange for sharing their health data, had grown substantially since its founding in 2004. By 2016 it had over 130 employees. However, convincing investors of the viability of the business model proves more challenging.
Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply.
- By
Reference 6212
Published 26 Sep 2016
Topic Operations
Region Global
Industry Biotechnology
Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply.
Facing reduced government funding, yet committed to broadening access to its services, Sankara Eye Care, a chain of hospitals in India, was at a crossroads in 2015. Over the years it had developed a lean operational model to provide free care to approximately 80 percent of its non-paying patients (cross-subsidized by paying patients).
- By
Reference 6124
Published 24 Apr 2015
Topic Operations
Region Asia
Industry Biotechnology
Facing reduced government funding, yet committed to broadening access to its services, Sankara Eye Care, a chain of hospitals in India, was at a crossroads in 2015. Over the years it had developed a lean operational model to provide free care to approximately 80 percent of its non-paying patients (cross-subsidized by paying patients).
Set in 2014, this case study examines the development and ongoing transition to value- and outcomes-based commissioning for diabetes care across North Central London (NCL). With the aim of improving health outcomes among their local populations, Clinical Commissioning Groups (CCGs) in NCL set out to transform the delivery and funding of services.
- By
Reference 6120
Published 23 Nov 2015
Topic Operations
Region Europe
Industry Biotechnology
Set in 2014, this case study examines the development and ongoing transition to value- and outcomes-based commissioning for diabetes care across North Central London (NCL). With the aim of improving health outcomes among their local populations, Clinical Commissioning Groups (CCGs) in NCL set out to transform the delivery and funding of services.
There are few industries in which the effects of technological innovation be seen as clearly as they can in the healthcare industry. Developments in devices, services and networks are in turn creating even more opportunities and innovation. This case looks specifically at developments in Stem Cell-related technologies, and the impact these might have on the treatment of certain diseases.
- By
Reference 5170
Published 01 Jan 2003
Topic Economics & Finance
Region Global
Industry Biotechnology
There are few industries in which the effects of technological innovation be seen as clearly as they can in the healthcare industry. Developments in devices, services and networks are in turn creating even more opportunities and innovation. This case looks specifically at developments in Stem Cell-related technologies, and the impact these might have on the treatment of certain diseases.
Technological and scientific innovation in recent years has opened many new lines of research and development in the field of cloning. Developments in agriculture and forestry have brought new approaches and methods in crop and forest production, and many more are predicted to emerge in the coming decade.
- By
Reference 5159
Published 11 Jan 2003
Topic Economics & Finance
Region Global
Industry Biotechnology, Environmental Services, Paper & Forest Products
Technological and scientific innovation in recent years has opened many new lines of research and development in the field of cloning. Developments in agriculture and forestry have brought new approaches and methods in crop and forest production, and many more are predicted to emerge in the coming decade.
Technological and scientific innovation in recent years has opened up much research and development in relation to human cloning. Many early steps have been taken and further progress is anticipated for the coming decade.
- By
Reference 5154
Published 01 Jan 2003
Topic Marketing
Region Global
Industry Biotechnology
Technological and scientific innovation in recent years has opened up much research and development in relation to human cloning. Many early steps have been taken and further progress is anticipated for the coming decade.